Yong-shi Li
TPQ 10002, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma.
Journal: Cancers
Published: August 29, 2019
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
Journal: Japanese journal of clinical oncology
Published: May 02, 2017
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Journal: Carcinogenesis
Published: October 18, 2014
STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 25, 2014
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Journal: Neoplasia (New York, N.Y.)
Published: February 24, 2014
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Journal: Molecular cancer therapeutics
Published: November 27, 2013
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Journal: Journal of hepatology
Published: August 27, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026